hepatitis
Novartis drops two drug candidates, takes $600 million hit
October 6, 2010Research and Development Human Genome Sciences, Novartis, candidiasis, hepatitis
Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …
BMS to acquire ZymoGenetics
September 8, 2010Research and Development, Sales and Marketing BMS, hepatitis
Bristol-Myers Squibb is to acquire biopharma company ZymoGenetics for $885 million to add to its ‘string of pearls’of small biotech …
New Pegasys licence gives patients ‘second chance for a cure’
December 4, 2008Sales and Marketing Roche, hepatitis
Hepatitis C patients who don't at first respond to treatment with Pegasys will now be able to receive the drug …
Call for universal Hepatitis B vaccination
August 22, 2008Sales and Marketing hepatitis
The pharma industry has joined up with patient groups to petition for universal Hepatitis B immunisation for all children in …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
August 14, 2026
